Credit Suisse’s Pliant Therapeutics PLRX Stock Holding History

Credit Suisse’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$969K	Buy	65,025 +3,143	+5%	+$51.8K	﹤0.01%	2289
2023 Q4	$1.12M	Buy	61,882 +4,122	+7%	+$62.7K	﹤0.01%	2268
2023 Q3	$1M	Sell	57,760 -4,996	-8%	-$86.6K	﹤0.01%	2304
2023 Q2	$1.14M	Buy	62,756 +22,281	+55%	+$527K	﹤0.01%	2297
2023 Q1	$1.08M	Buy	40,475 +7,008	+21%	+$200K	﹤0.01%	2280
2022 Q4	$647K	Buy	+33,467	New	+$700K	﹤0.01%	2618
2022 Q3	–	Sell	-13	Closed	–	–	4220
2022 Q2	$0	Buy	+13	New	+$83	﹤0.01%	4216
2021 Q3	–	Sell	-7,464	Closed	-$216K	–	4511
2021 Q2	$216K	Sell	7,464 -728	-9%	-$22.7K	﹤0.01%	4262
2021 Q1	$322K	Buy	+8,192	New	+$266K	﹤0.01%	3975

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Credit Suisse's PLRX Position: Q1 2024 in Review

Credit Suisse increased its Pliant Therapeutics (PLRX) stake by 5.1% in Q1 2024, buying an estimated $51.8K and bringing the position to 65,025 shares worth $969K. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

Credit Suisse first reported a position in PLRX in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.14M in Q2 2023. 135 funds tracked by Wall St. Rank hold PLRX as of Q1 2024.

Credit Suisse held 65,025 shares of Pliant Therapeutics worth $969K as of Q1 2024.
Credit Suisse bought 3,143 Pliant Therapeutics shares in Q1 2024, an estimated $51.8K.
Pliant Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2289 holding.
Credit Suisse first reported a position in Pliant Therapeutics in Q1 2021 and has held it in 9 quarters since.
Credit Suisse's Pliant Therapeutics position peaked at $1.14M in Q2 2023.
135 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.